GSK launches global creative review for pharma business

The fee on the account is estimated at $30 million.

GSK launches global creative review for pharma business

Pharmaceutical giant GlaxoSmithKline has issued a global creative review for its Rx business, which has an estimated fee of $30 million, according to people with knowledge of the matter.

The review, which Campaign US has learned is being handled internally and led by procurement, comes a year after GSK awarded its $1.7 billion media business to Publicis Media.

People with knowledge of the matter say the pharma account in review includes the respiratory and vaccine sectors, among others, which makes up about two-thirds of GSK’s business.

Some people in the industry indicate that this review is one of the biggest creative pitches of 2019 so far.

While the review is being run out of London, the majority of GSK’s revenue comes from the U.S. market. GSK has not yet responded to request for comment.

Most of the major holding companies have pieces of GSK’s pharma business, with IPG’s McCann Health leading the way. Representatives from McCann did not return calls for comment.

Commenting on the review, Greg Paull, principal at R3 Worldwide, said: "The challenge for GSK and others is that as some of their best performing drugs come off patent, they will continue to need impactful messaging to build engagement and loyalty."

The pharma giant awarded its $1.7 billion media business to Publicis Media in October last year. Publicis created a dedicated agency unit for the account.

At the time, GSK Consumer Healthcare VP and Global Head of Media Scott Grenz said: "We ran a very thorough and competitive pitch process with strong presentations from all companies, but ultimately Publicis was the best fit for us. We’re excited about the new partnership and the potential of the platformGSK model as we continue to progress our marketing transformation program."

The bespoke "platformGSK" model will bring together different expertise from across Publicis Media in healthcare, consumer strategy and digital business transformation.

The review, which was handled by ID Comms, came less than three years after GSK awarded its European business to MediaCom, with PHD handling the U.S. media work. Both agencies had retained the accounts in 2015 following a global media review. They first won the business in 2013.

Source:
Campaign US

Related Articles

Just Published

19 hours ago

40 Under 40 2024: Hajar Yusof, Naga DDB Tribal

Hajar’s initiatives reflect her commitment to innovation, diversity, and leaving a lasting legacy in the industry.

19 hours ago

Moo Deng says hands off unless you’ve washed up

Lifebuoy’s new campaign introduces a fresh face in hand hygiene, pairing AI with playful reminders to help keep those paws—er, hands—clean.

20 hours ago

The CMO's MO: Hyatt's APAC marketer on the power of ...

"Focus means saying no to 100 good ideas and saying yes to the great ones." Hyatt’s Tammy Ng shares how lessons from Steve Jobs and James Dyson are guiding her approach to personalising guest experiences.

20 hours ago

Trump’s victory isn’t just America’s crisis—it’s a ...

Make no mistake—2024’s US election was a calculated exercise in marketing from beginning to end, revealing a striking alignment with the very principles that drive our industry.